| 1 |
付晓菲，刘春生，宗景景，等.脓毒症引发急性肾损伤的生物标志物研究进展[J/CD].中华危重症医学杂志（电子版），2017，10(1):53-57.
|
| 2 |
Sime FB, Udy AA, Roberts JA. Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization[J]. Curr Opin Pharmacol, 2015 (24):1-6.
|
| 3 |
Udy AA, Roberts JA, Shorr AF, et al. Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients[J]. Crit Care, 2013, 17(1):R35.
|
| 4 |
Akers KS, Niece KL, Chung KK, et al. Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients[J]. J Trauma Acute Care Surg, 2014, 77(3 Suppl 2):S163-S170.
|
| 5 |
Hobbs AL, Shea KM, Roberts KM, et al. Implications of augmented renal clearance on drug dosing in critically ill patients: a focus on antibiotics[J]. Pharmacotherapy, 2015, 35(11):1063-1075.
|
| 6 |
Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?[J]. Clin Infect Dis, 2014, 58(8):1072-1083.
|
| 7 |
Udy AA, De Waele JJ, Lipman J. Augmented renal clearance and therapeutic monitoring of β-lactams[J]. Int J Antimicrob Agents, 2015, 45(4):331-333.
|
| 8 |
Udy AA, Jarrett P, Stuart J, et al. Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds[J]. Crit Care, 2014, 18(6):657.
|
| 9 |
Castellino P, Giordano C, Perna A, et al. Effects of plasma amino acid and hormone levels on renal hemodynamics in humans[J]. Am J Physiol, 1988, 255(3 Pt 2):F444-F449.
|
| 10 |
Moran P, Baylis PH, Lindheimer MD, et al. Glomerular ultrafiltration in normal and preeclamptic pregnancy[J]. J Am Soc Nephrol, 2003, 14(3):648-652.
|
| 11 |
Chagnac A, Weinstein T, Herman M, et al. The effects of weight loss on renal function in patients with severe obesity[J]. J Am Soc Nephrol, 2003, 14(6):1480-1486.
|
| 12 |
Vallon V, Blantz RC, Thomson S. Glomerular hyperfiltration and the salt paradox in early [corrected] type 1 diabetes mellitus: a tubulo-centric view[J]. J Am Soc Nephrol, 2003, 14(2):530-537.
|
| 13 |
Blantz RC, Steiner RW. Benign hyperfiltration after living kidney donation[J]. J Clin Invest, 2015, 125(3):972-974.
|
| 14 |
Dias C, Gaio AR, Monteiro E, et al. Kidney-brain link in traumatic brain injury patients? A preliminary report[J]. Neurocrit Care, 2015, 22(2):192-201.
|
| 15 |
Udy A, Jarrett P, Lassig-Smith M, et al. Augmented renal clearance (ARC) in traumatic brain injury (TBI): a single-center observational study of atrial natriuretic peptide, cardiac output, and creatinine clearance[J]. J Neurotrauma, 2016, 34(1):137-144.
|
| 16 |
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Defnitions for Sepsis and Septic Shock (Sepsis-3)[J]. JAMA, 2016, 315(8):801-810.
|
| 17 |
Udy AA, Roberts JA, Lipman J. Antibiotic pharmacok-inetic/pharmacodynamic considerations in the critically ill[M]. Singapore: Springer, 2018: 125-150.
|
| 18 |
De Waele JJ, Dumoulin A, Janssen A, et al. Epidemiology of augmented renal clearance in mixed ICU patients[J]. Minerva Anestesiol, 2015, 81(10):1079-1085.
|
| 19 |
Minkute R, Briedis V, Steponaviciūte R, et al. Augmented renal clearance--an evolving risk factor to consider during the treatment with vancomycin[J]. J Clin Pharm Ther, 2013, 38(6):462-467.
|
| 20 |
Campassi ML, Gonzalez MC, Masevicius FD, et al. Augmented renal clearance in critically ill patients: incidence, associated factors and effects on vancomycin treatment[J]. Rev Bras Ter Intensiva, 2014, 26(1):13-20.
|
| 21 |
Claus BO, Hoste EA, Colpaert K, et al. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy[J]. J Crit Care, 2013, 28(5):695-700.
|
| 22 |
Huttner A, Von Dach E, Renzoni A, et al. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study[J]. Int J Antimicrob Agents, 2015, 45(4):385-392.
|
| 23 |
Udy AA, Lipman J, Jarrett P, et al. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?[J]. Crit Care, 2015 (19):28.
|
| 24 |
Carlier M, Carrette S, Roberts JA, et al. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?[J]. Crit Care, 2013, 17(3):R84.
|
| 25 |
Blot S, Koulenti D, Akova M, et al. Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study[J]. Crit Care, 2014, 18(3):R99.
|
| 26 |
Chu Y, Luo Y, Qu L, et al. Application of vancomycin in patients with varying renal function, especially those with augmented renal clearance[J]. Pharm Biol, 2016, 54(12):1-8.
|
| 27 |
Baptista JP, Sousa E, Martins PJ, et al. Augmented renal clearance in septic patients and implications for vancomycin optimisation[J]. Int J Antimicrob Agents, 2012, 39(5):420-423.
|
| 28 |
唐莲，严晓薇，彭秋菊，等.肾功能亢进患者万古霉素血药浓度监测与临床疗效分析[J].中国医院药学杂志，2018，38(15):1629-1632.
|
| 29 |
Nakano T, Nakamura Y, Takata T, et al. Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis[J]. Int J Clin Pharm, 2016, 38(4):908-914.
|
| 30 |
Morata L, Cuesta M, Rojas JF, et al. Risk factors for a low linezolid trough plasma concentration in acute infections[J]. Antimicrob Agents Chemother, 2013, 57(4):1913-1917.
|
| 31 |
Parker S, Lipman J, Koulenti D, et al. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review[J]. Int J Antimicrob Agents, 2013, 42(4):289-293.
|
| 32 |
Goncalves-Pereira J, Martins A, Póvoa P. Pharmacokinetics of gentamicin in critically ill patients: pilot study evaluating the first dose[J]. Clin Microbiol Infect, 2010, 16(8):1258-1263.
|
| 33 |
Rea RS, Capitano B, Bies R, et al. Suboptimal amin-oglycoside dosing in critically ill patients[J]. Ther Drug Monit, 2008, 30(6):674-681.
|
| 34 |
Goboova M, Kuzelova M, Fazekas T, et al. The impact of therapeutic drug monitoring (TDM) in optimizing dosage regimens of gentamicin in patients with augmented renal clearance[J]. Int J Clin Pharm, 2016 (38):596.
|
| 35 |
Roberts JA, Cotta MO, Cojutti P, et al. Does critical illness change levofloxacin pharmacokinetics?[J]. Antimicrob Agents Chemother, 2015, 60(3):1459-1463.
|
| 36 |
Pai MP, Cojutti P, Pea F. Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥ 40 kg/m2) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring[J]. Clin Pharmacokinet, 2014, 53(8):753-762.
|
| 37 |
刘宁，张北源，刘洋，等.肾脏高溶质清除重症感染患者万古霉素合适初始剂量的临床研究[J].中华危重病急救医学，2018，30(7):646-651.
|
| 38 |
Bamgbola O. Review of vancomycin-induced renal toxi-city: an update[J]. Ther Adv Endocrinol Metab, 2016, 7(3):136-147.
|
| 39 |
何娟，毛恩强，景峰，等.重症急性胰腺炎伴肾功能亢进患者万古霉素的PK/PD研究[J].中华危重病急救医学，2017，29(9):810-814.
|
| 40 |
De Waele JJ, Carrette S, Carlier M, et al. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial[J]. Intensive Care Med, 2014, 40(3):380-387.
|
| 41 |
谢悦良，刘晶晶，吴翠芳，等.耐碳青霉烯类肺炎克雷伯菌肺部感染伴肾清除率增加患者的药学监护[J].中国临床药理学与治疗学，2016，21(10):1149-1154.
|